<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860518</url>
  </required_header>
  <id_info>
    <org_study_id>FP1CLI017</org_study_id>
    <nct_id>NCT04860518</nct_id>
  </id_info>
  <brief_title>Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With CoronavirUS</brief_title>
  <acronym>HIBISCUS</acronym>
  <official_title>A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faron Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faron Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blinded, randomized study is being conducted to see if the investigational new&#xD;
      drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help&#xD;
      patients recover more quickly from COVID-19 and prevent worsening of the condition. To&#xD;
      understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be&#xD;
      compared to dexamethasone.&#xD;
&#xD;
      Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6&#xD;
      consecutive days while hospitalized and will undergo daily assessments while in hospital for&#xD;
      a maximum of 28 days. Study specific assessments will be collected at pre-dose Day 1 through&#xD;
      Day 28 (PD and PIM assessments), in addition, clinical routine assessments will be utilized&#xD;
      for safety and efficacy assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will be performed in a double-blind and randomized manner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status at Day 14 (first day of study drug is Day 1) as measured by WHO 9-point ordinal scale</measure>
    <time_frame>Day 14</time_frame>
    <description>WHO 9-point ordinal scale:&#xD;
0 - No detectable infection&#xD;
- Not hospitalized, no limitations on activities&#xD;
- Not hospitalized, limitation on activities&#xD;
- Hospitalized, not requiring supplemental oxygen&#xD;
- Hospitalized, requiring supplemental oxygen&#xD;
- Hospitalized, on non-invasive ventilation or high flow oxygen devices&#xD;
- Hospitalized, on invasive mechanical ventilation&#xD;
- Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)&#xD;
- Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>As measured by WHO 9-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality at Day 28 and Day 90</measure>
    <time_frame>Day 28 and Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>IV IFN beta-1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN beta-1a</intervention_name>
    <description>Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised</description>
    <arm_group_label>IV IFN beta-1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Treated daily with dexamethasone as an IV bolus for 6 days while hospitalised</description>
    <arm_group_label>IV Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Positive SARS-CoV-2 test by PCR (polymerase chain reaction) or other diagnostic method&#xD;
             within the past 7 days&#xD;
&#xD;
          3. Admission to hospital with respiratory symptoms of COVID-19 requiring hospital care&#xD;
             and oxygen supplementation (≤ 8L/min)&#xD;
&#xD;
          4. Symptom onset no more than 7 days prior to hospital arrival&#xD;
&#xD;
          5. Informed consent from the subject or the subject's personal legal representative or a&#xD;
             professional legal representative must be available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to screen, randomize and administer study drug within 48 hours from arrival to&#xD;
             hospital&#xD;
&#xD;
          2. Systemic corticosteroid or baricitinib therapy within 7 days prior to arrival to&#xD;
             hospital or planned for the next days&#xD;
&#xD;
          3. Known hypersensitivity or contraindication to natural or recombinant IFN-beta-1a or&#xD;
             its excipients, or to dexamethasone or its excipients&#xD;
&#xD;
          4. Currently receiving IFN-beta-1a therapy&#xD;
&#xD;
          5. Home assisted ventilation (via tracheotomy or non-invasive) except for Continuous&#xD;
             Positive Airway Pressure (CPAP) / Bilevel Positive Airway Pressure (BIPAP) used only&#xD;
             for sleep-disordered breathing&#xD;
&#xD;
          6. Participation in another concurrent interventional pharmacotherapy trial during the&#xD;
             study period&#xD;
&#xD;
          7. Decision to withhold life-sustaining treatment; patient not committed to full support&#xD;
             (except DNR after cardiac arrest only)&#xD;
&#xD;
          8. Woman known to be pregnant, lactating or with a positive pregnancy test (urine or&#xD;
             serum test)&#xD;
&#xD;
          9. Subject is not expected to survive for 24 hours&#xD;
&#xD;
         10. Subject has liver failure (Child-Pugh grade C)&#xD;
&#xD;
         11. Any clinical condition that in the opinion of the attending clinician or Investigator&#xD;
             would present a risk for the subject to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Talmor, MD MPH,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deaconess Medical Center, Spokane, Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adit Ginde, MD MPH,</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarna Hannukainen, PhD</last_name>
    <phone>+358 02 469 5151</phone>
    <email>jarna.hannukainen@faron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerd Tötterman</last_name>
    <phone>+358 02 469 5151</phone>
    <email>gerd.totterman@faron.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adit Ginde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Talmor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry M Schrager, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd W Rice, MD, MSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

